Clinical trials: Dose-response Relationship
HIV Infections
A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient
To evaluate the safety and tolerance of the combination of adefovir dipivoxil at two comparative doses and nelfinavir plus saquinavir SGC administered orally (Group 1) vs.
- Trial name
- NCT00002184
- Testing
- Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 120 people
- Sponsor
- Gilead Sciences
Erectile Dysfunction, Depression
Depression Related Improvement With Vardenafil for Erectile Response
The study will last three months. During the first month of treatment the subject will receive either 10 mg vardenafil or placebo.
- Trial name
- DRIVER (NCT00661219)
- Testing
- Levitra (Vardenafil, BAY38-9456)
- Where
- 52 sites in United States, Canada and 3 more
- Volunteers
- 280 people
- Sponsor
- Bayer
HIV Infections
A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients
To determine the maximum tolerated dose of CI-1012 in late-stage HIV-1-infected patients. To determine the antiretroviral activity of CI-1012 when added to combination therapy.
- Trial name
- NCT00002218
- Testing
- CI-1012
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Parke-Davis
Fertilization
A Phase 2, Trial to Investigate the Dose-Response Relationship of a Single Injection of Org 36286 (Corifollitropin Alfa) to Initiate Multiple Follicular Growth in a Controlled Ovarian (Study 38826)(P06055)(COMPLETED)
The primary objective of this trial is to investigate the dose -response relationship of a single injection of Org 38286 to initiate multifollicular growth for the first seven days in a controlled ovarian hyperstimulation (COH)…
- Trial name
- NCT00598208
- Testing
- corifollitropin alfa, Follitropin beta injection
- Volunteers
- 325 people
- Sponsor
- Organon and Co
Diabetes Mellitus, Type I
Dose-Exposure-Response in Type 1 Diabetes Mellitus
To investigate the dose-exposure-response relationship of insulin glulisine (HMR1964) after single subcutaneous injections of 0.075, 0.15 and 0.3 U/kg body weight with the euglycaemic clamp technique using the Biostator (TM).
- Trial name
- NCT00368394
- Testing
- Insulin glulisine
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- Sanofi
Endometriosis
A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain
The main objective for this study is to assess the efficacy and dose-response relationship of ASP1707 in reduction of endometriosis associated pelvic pain.
- Trial name
- NCT01767090
- Testing
- ASP1707, Leuprorelin acetate
- Where
- 85 sites in Belgium, Bulgaria and 7 more
- Volunteers
- 912 people
- Sponsor
- Astellas Pharma Europe B.V.
Diabetes Mellitus Type 1
A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 Diabetes
The addition of BioChaperone to insulin lispro may accelerate the onset and shorten the duration of action of insulin lispro due to facilitation of the absorption of the insulin after subcutaneous injection.
- Trial name
- NCT02146651
- Testing
- BioChaperone insulin lispro 0.2U/Kg, BioChaperone insulin lispro 0.1U/Kg, BioChaperone insulin lispro 0.4U/Kg
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Adocia
Hypertension
A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension
A multicenter, randomized, double-blind, parallel, phase 2 study to assess dose-response relationship of HCP1803 in patients with essential hypertension
- Trial name
- HM_APOLLO (NCT03897868)
- Testing
- HCP1803, Amlodipine, Losartan
- Where
- South Korea
- Volunteers
- 248 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency
Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)
This is a multicenter, parallel-group, double-blind, randomized phase 4 study designed to identify the optimal dose of CE1226 (2 active doses) to slow disease progression as assessed by reduced rates of annual lung density…
- Conditions
- Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency, Emphysema
- Trial name
- NCT07326592
- Testing
- CE1226
- Where
- 2 sites in Denmark
- Volunteers
- 270 people
- Sponsor
- CSL Behring
HIV Infections
Safety and Effectiveness of Adding Adefovir Dipivoxil and Nelfinavir to the Anti-HIV Therapy of HIV-Infected Children
The purpose of this study is to see if it is safe and effective to give adefovir (a new anti-HIV drug) plus nelfinavir to HIV-infected children who are already receiving other anti-HIV medications.
- Trial name
- NCT00002219
- Testing
- Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Gilead Sciences
HIV Infections, HIV Wasting Syndrome
Growth Hormone in the Treatment of HIV-Associated Wasting
The purpose of this study is to compare physical function and lean body mass in patients getting different doses of somatropin compared to patients not getting the drug.
- Trial name
- NCT00489528
- Testing
- Somatropin; Recombinant human growth hormone (r hGH)
- Sponsor
- EMD Serono
Posttraumatic Stress Disorder
Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD
The goal of this clinical trial is to learn if MDMA in combination with therapy is safe and effective in people with chronic, treatment-resistant PTSD.
- Trial name
- NCT01793610
- Testing
- Comparator Dose (40mg) MDMA HCl, Active Dose 2 (100 mg) MDMA HCl, Active Dose 1 (125 mg) MDMA HCl
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Resilient Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients
This is a randomised, double-blind, placebo controlled, parallel group study to evaluate the safety, tolerability, pharmacokinetics and dose response of multiple doses of GSK2269557 administered as a dry powder in COPD subjects.
- Trial name
- NCT02130635
- Testing
- GSK2269557 100 MCG, GSK2269557 500 MCG
- Where
- 2 sites in Germany
- Volunteers
- 64 people
- Sponsor
- GlaxoSmithKline
Candidiasis, Oral, HIV Infections
Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole
The purpose of this study is to see if it is safe and effective to give L-743,872 to patients with thrush, an AIDS-related yeast infection of the mouth, that has not been cured with fluconazole treatment.
- Trial name
- NCT00005920
- Testing
- L-743,872
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Merck Sharp & Dohme LLC
Bipolar Depression
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Lurasidone HCI is a compound that is a candidate for the treatment of bipolar I depression. This clinical study is designed to test the hypothesis that Lurasidone in combination with either Lithium or Divalproex is effective…
- Trial name
- PREVAIL3 (NCT01284517)
- Testing
- Lurasidone
- Where
- 75 sites in United States, Canada and 8 more
- Volunteers
- 356 people
- Sponsor
- Sumitomo Pharma America, Inc.
Meningitis, Cryptococcal, HIV Infections
Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis
The purpose of this study is to examine the antifungal activity of recombinant interferon-gamma 1b (rIFN-gamma 1b) given with standard antifungal therapy.
- Trial name
- NCT00012467
- Testing
- Itraconazole, Flucytosine, Fluconazole
- Where
- 9 sites in United States, Peru
- Volunteers
- 60 people
- Sponsor
- InterMune
Candidiasis, Oral, HIV Infections
Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment
The purpose of this study is to see if it is safe and effective to give Lamisil to HIV-positive patients with thrush (a fungal infection) that has not responded to fluconazole.
- Trial name
- NCT00002394
- Testing
- Terbinafine hydrochloride
- Where
- 9 sites in United States
- Volunteers
- 30 people
- Sponsor
- Novartis